Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Selective breast cancer treatment with minimal side effects remains a challenge.
• Cytochrome P450 (CYP) enzymes influence cancer cell proliferation, signaling, and drug metabolism.
• CYP isoforms are critical in metabolizing steroid hormones and xenobiotics involved in breast cancer development.

Purpose of the Study:

• To review the impact of CYP expression on standard of care (SoC) drugs for breast cancer.
• To explore therapeutic intervention opportunities by exploiting CYP expression.
• To outline future research directions for developing breast cancer drugs with improved therapeutic indices.

Main Methods:

• Literature review of existing research on CYP enzymes in breast cancer.
• Analysis of the role of specific CYP isoforms in breast cancer pathogenesis and treatment.
• Discussion of current therapeutic strategies and potential novel approaches targeting CYP pathways.

Main Results:

• CYP expression significantly impacts the efficacy and toxicity of standard breast cancer therapies.
• Specific CYP isoforms are implicated in both the development and progression of breast cancer.
• Targeting CYP enzymes presents a promising avenue for personalized breast cancer treatment.

Conclusions:

• A deeper understanding of CYP expression is essential for optimizing breast cancer treatment.
• Exploiting CYP pathways can lead to more selective and effective therapies with reduced side effects.
• Future research should focus on elucidating CYP functions to develop improved drugs for breast cancer patients.